Vancomycin hydrochloride
Product Description
Xellia Pharmaceuticals ApS
-
Country/Region:Denmark
-
Founded:1903
-
On CPHI since:2015
-
Certificates:4
-
Employees:1000 - 4999
Company types
Primary activities
Xellia Pharmaceuticals ApS
-
Country/Region:Denmark
-
Founded:1903
-
On CPHI since:2015
-
Certificates:4
-
Employees:1000 - 4999
Company types
Primary activities
More Products from Xellia Pharmaceuticals ApS (20)
-
Product Daptomycin vials
Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.
Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus au... -
Product Daptomycin RT
Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.
Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus aureus... -
Product Polymyxin B vials
Polymyxin B is a mixture of the sulfates of polypeptide antibiotics active against almost all gram-negative bacteria except the Proteus group.
Indication: Used in the treatment of patients with acute urinary, meningeal or blood-stream infections due to susceptible ... -
Product Dalbavancin - Pipeline
US DMF Submitted & Under registration in Europe -
Product Colistimethate sodium
Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Indication: Used in the treatment of acute or chronic inf... -
Product Fidaxomicin
Product Pipeline -
Product Amphotericin B
Amphotericin B is a mixture of polyenes active against a wide variety of fungi e.g. Aspergillus, Candida and Cryptococcus species.
Indication: Used in the treatment of severe, invasive, potentially life-threatening fungal infections (mycosis) typically in immunocompromised... -
Product Bacitracin
Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.
Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants... -
Product Bacitracin zinc
Bacitracin zinc is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci. The zinc complex adds stability to the component, making bacitracin zinc more stable compared to bacitracin.
Indication: Used i... -
Product Colistimethate sodium (CMS)
Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
... -
Product Daptomycin
Daptomycin is a lipopeptide antibiotic active against gram-positive bacteria such as Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isol... -
Product Gramicidin
Gramicidin is a mixture of linear polypeptides active against a variety of gram-positive bacteria.
Indication: Ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacter...
Xellia Pharmaceuticals ApS resources (3)
-
Datasheet Xellia Corporate Introduction
Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers. -
Video Xellia Pharmaceuticals - We're your people
We are more than an API company. We are built on long standing relationships that have stood the test of time. Why? Because for 120 years we have been developing the anti-infectives the world needs. But we are evolving and in the future, we won't be known just for anti-infectives. Our ambition? To be the leading global supplier of APIs across many therapeutic areas. -
Brochure Xellia Pharmaceuticals Sustainability Report
Sustainability, the way we do everything else - honestly.
We make medicines that save lives. That's a responsibility we take seriously, in every direction — including the one that points toward the planet and the people we share it with.
Our 2025 Sustainability Report is out, and it tells a simple story: we're doing the work. Real numbers, real progress, real accountability — from our fermentation tanks in Copenhagen to our production lines in Budapest and Taizhou.
No greenwashing. No vague promises. Just a clear, honest look at where we stand and where we're headed — reviewed and signed off by our Executive Management team, because this matters enough to get right from the top.